Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value

$18.75+0.61 (+3.36%)

Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –

Acadia Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2014 it was -$93.02M.

Period	Period end	Value	Change
FY2014	Dec 31, 2014	-$93.02M	–
FY2013	Dec 31, 2013	-$38.22M	–
FY2012	Dec 31, 2012	-$20.78M	–
FY2011	Dec 31, 2011	-$22.57M	–

Parsed from the XBRL in Acadia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACAD.

Revenue growth14.8% · median 19.8%

Gross margin90.5% · median 84.5%

Operating margin10.2% · median 7.0%

Net margin30.1% · median -2.6%

Advertisement
300 × 250

See a number that looks wrong?